Wyeth-Ayerst Acel-Imune Discontinued; DTaP Vaccine Had Sales Of $71 Mil.
Executive Summary
Wyeth-Ayerst is discontinuing the DTaP vaccine Acel-Imune, the company said.
You may also be interested in...
Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?
Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon
Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?
Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon
Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market
Aventis-Pasteur is in discussions with FDA and the Centers for Disease Control & Prevention on ways to increase the supply of its influenza vaccine Fluzone following Wyeth's decision to discontinue FluShield